Italia markets open in 8 hours 7 minutes

Esperion Therapeutics, Inc. (0IIM.L)

LSE - LSE Prezzo differito. Valuta in USD.
Aggiungi a watchlist
5,82-0,41 (-6,56%)
Alla chiusura: 02:59PM BST
Schermo intero
Chiusura precedente6,23
Aperto6,00
Denaro0,00 x N/D
Lettera0,00 x N/D
Min-Max giorno5,82 - 6,00
Intervallo di 52 settimane5,82 - 6,00
Volume98
Media VolumeN/D
Capitalizzazione188,631M
Beta (5 anni mensile)0,43
Rapporto PE (ttm)N/D
EPS (ttm)-6,24
Prossima data utili01 ago 2022 - 05 ago 2022
Rendimento e dividendo (forward)N/D (N/D)
Data ex dividendoN/D
Stima target 1AN/D
  • GlobeNewswire

    Esperion to Participate in Upcoming H.C. Wainwright Global Investment Conference

    ANN ARBOR, Mich., May 17, 2022 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR), today announced that President and Chief Executive Officer, Sheldon Koenig, will participate in a fireside chat at the upcoming H.C. Wainwright Global Investment Conference on Tuesday, May 24th, 2022. Event:H.C. Wainwright Global Investment ConferenceDate:Tuesday, May 24th, 2022Format:Presentation and 1:1 MeetingsTime:7:00 am Eastern Standard TimeWebcast:Link A live audio webcast can be accessed on the investor and media

  • GlobeNewswire

    Esperion Reports First Quarter 2022 Financial Results and Provides Company Update

    – Unprecedented CLEAR Outcomes Study Approaching 95% MACE Accumulation– – U.S. Net Product Revenue of NEXLETOL® (bempedoic acid) Tablets and NEXLIZET® (bempedoic acid and ezetimibe) Tablets Grew approximately 109% Y/Y to $13.4 Million in the First Quarter 2022– – Retail Prescription Equivalents Grew 56.7% Year over Year – ANN ARBOR, Mich., May 03, 2022 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today reported financial results for the first quarter ended March 31, 2022 and provided a business u

  • GlobeNewswire

    Esperion Announces Publication of CLEAR Harmony Open-Label Extension Study Data for Bempedoic Acid in the American Journal of Cardiology

    Analysis of open-label extension data demonstrated that bempedoic acid was generally well tolerated and demonstrated sustained efficacy with up to 2.5 years of continuous treatmentANN ARBOR, Mich., May 02, 2022 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced the publication of data from the CLEAR Harmony Open-Label Extension (OLE) Study of bempedoic acid, also known as NEXLETOL®, in the American Journal of Cardiology. The paper, “Long-term Safety and Efficacy of Bempedoic Acid in Pat